

Supplementary Table 3. Univariate and multivariate Cox regression analysis in cohort of patients with stage III NSCLC treated with CRT and durvalumab.

| Progression-free survival | Univariate Hazard Ratio [95%CI] | P-value | Multivariate Hazard ratio [95%CI] | P-value |
|---|---------------------------------|---------|-----------------------------------|---------|
| Aneuploidy (low vs high) | 0.72 [0.49-1.05] | 0.08 | 0.63 [0.41-0.95] | 0.03 |
| Age* | 0.98 [0.96-1.01] | 0.32 | - | - |
| Sex (male vs female) | 0.96 [0.67-1.37] | 0.83 | - | - |
| ECOG | | | | |
| PS 0 | - | - | - | - |
| PS 1 | 1.78 [0.66-0.88] | 0.004 | 1.78 [1.17-2.72] | 0.007 |
| PS 2 | 1.87 [0.79-4.42] | 0.15 | 1.68 [0.57-4.95] | 0.35 |
| Stage 8th AJCC | | | | |
| IIIA | - | - | - | - |
| IIIB | 1.58 [1.03-2.41] | 0.03 | 1.56 [0.95-2.54] | 0.07 |
| IIIC | 2.07 [1.24-3.46] | 0.006 | 1.38 [1.36-4.23] | 0.002 |
| Histology (NSQ vs Squamous) | 0.86 [0.57-1.31] | 0.50 | - | - |
| Smoking history (ever vs never) | 0.93 [0.45-1.91] | 0.84 | - | - |
| TMB tertiles | | | | |
| Lower | - | - | - | - |
| Middle | 0.77 [0.50-1.18] | 0.23 | 0.71 [0.44-1.15] | 0.16 |
| Upper | 0.37 [0.24-0.59] | <0.0001 | 0.31 [0.18-0.52] | <0.0001 |
| PD-L1 TPS (≥90 vs <90%) | 0.36 [0.18-0.71] | 0.003 | 0.48 [0.22-0.88] | 0.03 |
| | | | | |
| Overall Survival | Univariate Hazard Ratio [95%CI] | P-value | Multivariate Hazard ratio [95%CI] | P-value |
| Aneuploidy (low vs high) | 0.51 [0.28-0.91] | 0.02 | 0.50 [0.27-0.92] | 0.03 |
| Age* | 1.02 [0.98-1.06] | 0.22 | - | - |
| Sex (male vs female) | 0.94 [0.656-1.57] | 0.81 | - | - |
| ECOG | | | | |
| PS 0 | - | - | - | - |
| PS 1 | 1.78 [0.77-2.34] | 0.29 | 1.19 [0.64-2.25] | 0.56 |
| PS 2 | 2.63 [0.89-7.61] | 0.08 | 2.12 [0.58-7.78] | 0.25 |
| Stage 8th AJCC | | | | |
| IIIA | - | - | - | - |
| IIIB | 1.29 [0.70-2.38] | 0.41 | 1.76 [0.83-3.74] | 0.13 |
| IIIC | 2.07 [1.02-4.20] | 0.044 | 2.58 [1.15-5.78] | 0.021 |
| Histology (NSQ vs Squamous) | 0.62 [0.35-1.10] | 0.10 | - | - |
| Smoking history (ever vs never) | 0.98 [0.48-1.97] | 0.99 | - | - |
| TMB tertiles | | | | |
| Lower | - | - | - | - |
| Middle | 1.07 [0.57-2.02] | 0.81 | 0.89 [0.40-1.94] | 0.77 |
| Upper | 0.69 [0.36-1.30] | 0.15 | 0.63 [0.30-1.31] | 0.20 |
| PD-L1 TPS (≥90 vs <90%) | 0.39 [0.14-1.07] | 0.07 | 0.36 [0.08-1.45] | 0.12 |

*Age as continuous variable

PFS HR and P-value for aneuploidy after interaction term with PD-L1 and ECOG PS are 0.65 and 0.042, respectively.

OS HR and P-value for aneuploidy after interaction term with PD-L1 and ECOG PS are 0.49 and 0.04, respectively.